Skip to main content

Positive Report for Zymeworks (ZYME) from Wells Fargo

Tipranks - Tipranks - Sat Dec 13, 2025

Zymeworks received a Buy rating and a price target from Wells Fargo analyst Eva Fortea Verdejo today.

Claim 50% Off TipRanks Premium and Invest with Confidence

Fortea Verdejo covers the Healthcare sector, focusing on stocks such as Zymeworks, Merus, and Xencor. According to TipRanks, Fortea Verdejo has an average return of 61.2% and an 89.47% success rate on recommended stocks.

In addition to Wells Fargo, Zymeworks also received a Buy from Citi’s Yigal Nochomovitz in a report issued on December 4. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Zymeworks (NASDAQ: ZYME).

See the top stocks recommended by analysts >>

Based on Zymeworks’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $27.61 million and a GAAP net loss of $19.6 million. In comparison, last year the company earned a revenue of $16 million and had a GAAP net loss of $29.85 million

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).